

High-throughput Antiviral Assays


Southern Research works diligently and quickly to respond to new and emerging needs in antiviral discovery.

Our experts are ready to partner at various stages of the drug development process, from early discovery through clinical studies. Our high-throughput options provide an economical and efficient way to explore a large number of compounds—both small molecule and biologics. All antiviral assays include parallel cytotoxicity evaluation.


Virus	Containment Level	Virus Strain/ Isolate	Cell Line	Assays available
SARS-CoV-2	BSL-3	Jn.1, Delta, Omicron, USA_WA1/2020	Vero E6	CPE
SARS-CoV-2	BSL-3	USA_WA1/2020	A549 (expressing ACE2)	IF
SARS-CoV-2	BSL-3	SARS CoV-2 Nanoluc reporter	A549 (expressing ACE2)	Nanoluc reporter
SARS-CoV	BSL-3	Toronto 2	Vero E6	CPE
MERS	BSL-3	Human Beta-Coronavirus LineageC-Novel/2012	Vero CCL-81	CPE
Human Coronavirus	BSL-2	229E	Huh7	CPE
Influenza	BSL-2	H1N1 (A/Ca/07/09)	A549, MDCK	IF, CPE
Influenza	BSL-2	H1N1 (A/WSN/33)	A549, MDCK	IF, CPE
Influenza	BSL-2	H3N2 (A/Udom/72)	A549, MDCK	IF,CPE
Influenza	BSL-2	H3N2 A/Brisbane/10/07	A549	IF
Influenza	BSL-3	H7N7 A/mallard/Netherlands/12/00	A549	IF
Influenza	BSL-3	H7N9 A/Anhui/1/13	MDCK	CPE
Influenza	BSL-3	H5N1 A/Vietnam/ 1203/2004 (HPAI)	MDCK	CPE
Influenza	BSL-2	B/Florida/4/2006	A549	IF
Influenza	BSL-2	B/Brisbane/60/2008	A549	IF
RSV	BSL-2	Long	HEp-2	CPE
HMPV	BSL-2	GFP reporter virus; parental strain CAN97-83	LLC-MK2	GFP reporter
HIV-1	BSL-2	IIIB-CEM.SS, HIV-1 KER2008, HIV-1 NL4-3	PBMC	AlphaLISA detecting p24
HIV-1	BSL-2	NL4-3	MT-4	CPE
HSV-1	BSL-2	KOS	Vero CCL-81	CPE
Dengue	BSL-2	Dengue 2 (New Guinea C)	HEK 293	CPE, IF
Zika	BSL-2	Paraiba 2015 isolate	Vero CCL-81	IF
Chikungunya	BSL-2	vaccine strain 181/25	Vero CCL-81	CPE
DHODH	BSL-2	biochemical assay (host target)		enzymatic

Changes in standard protocols will incur an assay development fee.
3D human tissue air-liquid interface model available for respiratory viruses.

**Remdesivir Inhibition of SARS-CoV-2
Nanoluc Reporter Virus in A549 cells**



**VX-787 Inhibition of Influenza
A/WSN/33, H1N1, in A549 cells**



Our offerings are constantly being updated.
Additional options are available for alternate *in vitro* formats and *in vivo* studies.

**Our range of experience and our capacity to deliver
can enhance your antiviral programs.**